Nivolumab is cleared for treating patients with metastatic RCC whose disease advanced despite prior treatment with anti-angiogenic therapy.
For patients with diabetes, poor glycemic control linked to higher risk of post-operative progression.
Specific alterations seen in type 1 and type 2 carcinomas; type 2 consists of at least 3 subtypes.
Dialysis, organ transplant may increase odds for certain types of cancer.
High-heat cooking methods implicated in new study.
On-treatment neutropenia and hypertension are independently associated with decreased mortality risk.
Researchers report a survival advantage over observation among elderly patients with localized tumors.
Case report describes 84-year-old male patient with myositis after nivolumab treatment.
Higher stroke risk found in older kidney cancer patients taking the drugs.
The model incorporates 2 newly identified independent mortality risk factors in patients requiring second-line targeted therapy.
Active surveillance equal to partial nephrectomy for renal function preservation.
In separate studies, nivolumab prolonged overall survival and cabozantinib improved progression-free survival compared with everolimus.
Trend mirrors move to targeted therapy era.
Higher risk for clear cell, papillary renal cell carcinoma, but not chromophobe histology.
Increased risk for treatment-related subsequent neoplasms even beyond age 40 years.
Quality of life can be improved without adversely affecting outcomes.
New data suggest a prognosis role for the neutrophil to lymphocyte ratio.
Completely intracorporeal robotic level III inferior vena cava tumor thrombectomy viable.
Older adults react differently to treatment, oncology group notes.
Almost 1 in 3 not told cancer treatment might affect future fertility.
No improvement in quality of life, even for patients with good baseline performance status.
Radical and partial nephrectomy for renal cell carcinoma are associated with a similar risk of end-stage renal disease (ESRD), according to research.
High dietary intake of this antioxidant decreased the risk of renal cell carcinoma, according to a recent meta-analysis.
In a study, the treatment was associated with a 53% decreased risk of death from kidney cancer compared with expectant management.
Bevacizumab, sorafenib, and temsirolimus combinations did not improve progression-free survival in renal cell carcinoma (RCC).
80% of lung cancer deaths linked to smoking, researchers say.
Asymptomatic presentation, T3 low-grade tumors, and negative lymph nodes are associated with better progression-free and overall survival.
Study findings contradict those of previous investigators.
Two-thirds of patients feel that tumor profiling could improve their treatment; many will pay out of pocket.
- Prostate Cancer ADT May Increase Thromboembolic Disease Risk
- Home-Cooked Meals Linked to Lower Risk of Type 2 Diabetes
- Social Jetlag Linked to Prediabetes, Cardiovascular Disease Risk
- Risk Factors for HD Patient Hospitalization for Infections Identified
- Prostate Cancer ADT Strategies Offer Similar Efficacy, QoL
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)